Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease
https://doi.org/10.14412/1996-7012-2019-4-96-98
Abstract
The paper discusses the results of using methotrexate (MTX) in real clinical practice in a patient with calcium pyrophosphate crystal deposition resistant to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs, and hydroxychloroquine) It demonstrates the efficiency and possibility of safely using MTX at a dose of 20 mg/week during a year.
About the Authors
E. V. Ilyinykh
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Ekaterina Valerievna Ilyinkh
34A, Kashirskoe Shosse, Moscow 115522
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Johnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage (review). Front Biosci. 2005 Jan 1;10:988-97. Print 2005 Jan 1.
2. Barskova VG. Diagnosis of calcium pyrophosphate crystal deposition disease (pyrophosphate arthropathy). Russkii meditsinskii zhurnal. 2012;(7):350-3. (In Russ.).
3. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011 Apr;70(4):563-70. doi: 10.1136/ard.2010.139105. Epub 2011 Jan 7.
4. Tedeschi SK. Issues in CPPD Nomenclature and Classification. Curr Rheumatol Rep. 2019 Jul 25;21(9):49. doi: 10.1007/s11926-019-0847-4.
5. Bencardino JT, Hassankhani A. Calcium pyrophosphate dihydrate crystal deposition disease. Semin Musculoskelet Radiol. 2003 Sep;7(3):175-85.
6. Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98): 32-8. Epub 2016 Jul 22.
7. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part II: managment. Ann Rheum Dis. 2011 Apr;70(4):571-5. doi: 10.1136/ard.2010.139360. Epub 2011 Jan 20.
8. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986 Aug;13(4):804-5.
9. Vladimirov SA, Eliseev MS. Current strategy in the treatment of calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(6):746-52. (In Russ.). doi: 10.14412/1995-4484-2018-746-752
10. Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007 Feb;56(2):688-92.
11. Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201. (In Russ.). doi: 10.14412/1995-4484-2018-196-201
12. Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008 Jul;58(7): 2210-1. doi: 10.1002/art.23552.
13. Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5): 458. doi: 10.1186/s13075-014-0458-4.
14. Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012 Aug;18(5): 234-6. doi: 10.1097/RHU.0b013e3182611471.
15. Cheung HS. Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol. 2000 May;12(3):223-7.
16. Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol. 2005 May;17(3): 314-8.
17. Cheung HS. Biologic effects of calciumcontaining crystals [review]. Curr Opin Rheumatol. 2005 May;17(3):336-40.
18. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72.
19. Seitz M. Molecular and cellular effects of methotrexate [review]. Curr Opin Rheumatol. 1999 May;11(3):226-32.
20. Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin [published erratum appears in Arthritis Rheum 1993; 36:1028]. Arthritis Rheum. 1993 May;36(5): 613-9.
21. Finckh А, Mc Carthy GM, Madigan A. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5):458. doi: 10.1186/s13075-014-0458-4.
22. Campillo-Gimenez L, Renaudin F, Jalabert M, et al. Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK Pathways. Front Immunol. 2018 Oct 9;9:2248. doi: 10.3389/fimmu.2018.02248. eCollection 2018.
Review
For citations:
Ilyinykh EV, Eliseev MS. Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(4):96-98. (In Russ.) https://doi.org/10.14412/1996-7012-2019-4-96-98
Views:
683
Email this article 